H.C. Wainwright lowered the firm’s price target on Sensus Healthcare (SRTS) to $8 from $12 and keeps a Buy rating on the shares. The firm cites the company’s Q2 sales miss for the target cut.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRTS:
- Sensus Healthcare price target lowered to $6 from $13 at Lake Street
- Sensus Healthcare Reports Q2 2025 Financial Results
- Sensus Healthcare reports Q2 EPS (6c), consensus 1c
- Sensus Healthcare superficial radiation therapy systems get MDSAP certification
- Sensus Healthcare enters strategic agreement with Radiology Oncology Systems